{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03784924",
            "orgStudyIdInfo": {
                "id": "430"
            },
            "organization": {
                "fullName": "University of Michigan",
                "class": "OTHER"
            },
            "briefTitle": "EDRN Prostate MRI Biomarker Study",
            "officialTitle": "EDRN Prostate MRI Biomarker Study and Reference Set",
            "acronym": "P-MRI",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "edrn-prostate-mri-biomarker-study"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-02",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2019-02-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2028-06-30",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2028-12-31",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2018-12-04",
            "studyFirstSubmitQcDate": "2018-12-19",
            "studyFirstPostDateStruct": {
                "date": "2018-12-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-02-22",
            "lastUpdatePostDateStruct": {
                "date": "2024-02-23",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "John Wei",
                "investigatorTitle": "David A Bloom Professor of Urology, Medical Director of Brighton Center for Specialty Care and Professor of Urology, Medical School",
                "investigatorAffiliation": "University of Michigan"
            },
            "leadSponsor": {
                "name": "University of Michigan",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "The University of Texas Health Science Center at San Antonio",
                    "class": "OTHER"
                },
                {
                    "name": "University of Alabama at Birmingham",
                    "class": "OTHER"
                },
                {
                    "name": "University of Chicago",
                    "class": "OTHER"
                },
                {
                    "name": "Cornell University",
                    "class": "OTHER"
                },
                {
                    "name": "H. Lee Moffitt Cancer Center and Research Institute",
                    "class": "OTHER"
                },
                {
                    "name": "Vanderbilt University",
                    "class": "OTHER"
                },
                {
                    "name": "Emory University",
                    "class": "OTHER"
                },
                {
                    "name": "University of Miami",
                    "class": "OTHER"
                },
                {
                    "name": "University of Texas",
                    "class": "OTHER"
                },
                {
                    "name": "Beth Israel Deaconess Medical Center",
                    "class": "OTHER"
                },
                {
                    "name": "Brigham and Women's Hospital",
                    "class": "OTHER"
                },
                {
                    "name": "Fred Hutchinson Cancer Center",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The commercialization of MRI fusion biopsies has resulted in a dramatic increase in the use of MRI imaging for prostate cancer. How best to use MRI in the initial prostate biopsy setting given the availability of validated prostate cancer early detection markers is uncertain.This study will allow investigators to determine if prostate MRI is superior to validated panel of laboratory biomarkers (e.g. PCA3, PSA and TMPRSS2:ERG) in the initial biopsy setting.",
            "detailedDescription": "The primary aim of this study is to see if the addition of prostate MRI to a panel consisting of PSA, PCA3, TMPRSS2:ERG will significantly improve specificity for high-grade prostate cancer by 10%. The subsequent exploratory aims will 1) create an optimal panel of urine, blood and tissue biomarkers that will select those cases most likely to benefit from a MRI targeted biopsy, 2) directly compare PSA and urinary biomarkers with MRI to determine which ones are value added in the setting of initial biopsy, 3) evaluate changes in these biomarkers and MRI to determine if longitudinal changes predict subsequent high-grade prostate cancer, and 4) optimize MRI imaging to improve test performance. Importantly, this study will create a unique, prospective, cohort that will become the foundational reference set for of a range of future biomarker studies."
        },
        "conditionsModule": {
            "conditions": [
                "PSA",
                "Prostate Cancer"
            ],
            "keywords": [
                "Prostate cancer",
                "psa",
                "early detection",
                "MRI"
            ]
        },
        "designModule": {
            "studyType": "OBSERVATIONAL",
            "patientRegistry": false,
            "designInfo": {
                "observationalModel": "COHORT",
                "timePerspective": "PROSPECTIVE"
            },
            "bioSpec": {
                "retention": "SAMPLES_WITH_DNA",
                "description": "8 x 250ul and 10 x 100ul Serum 10 x 200ul EDTA Plasma\n\n1 x 500ul Buffy Coat\n\n1 x 1ml Whole Blood from EDTA Tube 2 x 1ml Unprocessed Raw Urine 2 x 2.5ml Whole Urine 2 x 5ml Supernatant\n\n1 x 50ul Pellet/Sediment FFPE tumor tissue (blocks) from all cancer foci Nitrocellulose tissue prints from all cores"
            },
            "enrollmentInfo": {
                "count": 1500,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Initial prostate biopsy",
                    "description": "Men who have never had a prostate biopsy, but have an elevated risk for prostate cancer such as elevated PSA who are scheduled or considered candidate for an initial prostate biopsy.",
                    "interventionNames": [
                        "Diagnostic Test: MRI prostate"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DIAGNOSTIC_TEST",
                    "name": "MRI prostate",
                    "description": "MRI and laboratory biomarkers",
                    "armGroupLabels": [
                        "Initial prostate biopsy"
                    ],
                    "otherNames": [
                        "urine and blood biomarkers"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Clinically significant prostate cancer",
                    "description": "Pathologic diagnosis of prostate cancer with at least Gleason 7 or worse cancer grade on a needle biopsy",
                    "timeFrame": "2 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Men with suspected but undiagnosed prostate cancer\n* To be scheduled/scheduled for biopsy as routine clinical care\n\nExclusion Criteria:\n\n* Inability to obtain blood and urine per SOP or conduct an attentive DRE\n* Unable to undergo/tolerate a prostate MRI or failure to conduct the MRI\n* Prior diagnosis of prostate cancer\n* Prior prostate MRI unless being used as Index MRI (in this case index MRI can be one year prior to consent date)\n* Participating in clinical trial for prostate disease\n* Prior prostate surgery such as TURP, TUNA, TUMT, HOLEP, REZUM, UROlift\n* Prior PCA3, TMPRSS2:erg or MIPS panel performed for clinical purpose",
            "healthyVolunteers": false,
            "sex": "MALE",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ],
            "studyPopulation": "Urology clinics",
            "samplingMethod": "NON_PROBABILITY_SAMPLE"
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jackie Dahlgren",
                    "role": "CONTACT",
                    "phone": "206-667-3438",
                    "email": "jdahlgre@fredhutch.org"
                }
            ],
            "overallOfficials": [
                {
                    "name": "John T Wei, MD, MS",
                    "affiliation": "University of Michigan",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Michigan",
                    "status": "RECRUITING",
                    "city": "Ann Arbor",
                    "state": "Michigan",
                    "zip": "48109",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "John T Wei, MD",
                            "role": "CONTACT",
                            "phone": "734-615-3040",
                            "email": "jtw@med.umich.edu"
                        },
                        {
                            "name": "Rabia Martin",
                            "role": "CONTACT",
                            "phone": "7347637508",
                            "email": "rabia@med.umich.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.27756,
                        "lon": -83.74088
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}